Business Context and Reporting Period
This Form 8-K is a Current Report filed by Vivos Therapeutics, Inc. on October 24, 2025. The company is incorporated in Delaware and its common stock (Ticker: VVOS) trades on The NASDAQ Stock Market LLC. The filing addresses a specific corporate action regarding its capital raising activities.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics. The document is a procedural report regarding a securities offering update.
Material Changes
- Offering Price Increase: On October 24, 2025, the Company filed a prospectus supplement to increase the aggregate offering price of shares issuable under its At The Market (ATM) Offering Agreement with H.C. Wainwright & Co., dated February 14, 2025.
- Legal Opinion: The filing includes an opinion from Ellenoff Grossman & Schole LLP regarding the legality of the issuance and sale of the shares.
Guidance, Outlook, and Risks
The filing does not provide management commentary, financial guidance, or an outlook for future periods. It does not disclose specific risks or contingencies beyond the standard legal opinion attached as an exhibit.
Investor Verification Checklist
- Verify the specific dollar amount of the increased aggregate offering price in the referenced prospectus supplement (not detailed in this 8-K text).
- Review the terms of the original At The Market Offering Agreement dated February 14, 2025, to understand the scope of the increase.
- Confirm the number of shares remaining available for issuance under the updated agreement.